🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Though virtual, learning a tremendous amount on how to write and conduct clinical trials at the ASCO/AACR Vail workshop ASCO AACR #PDG3 #ThoracicOncology

authors.elsevier.com/c/1eDIjcYZOTc78. Read about the prognostic/predictive value of neutrophil-to-lymphocyte ratio in patients with stage III NSCLC. In collaboration with our VA oncology, Thoracic Oncology, and Radiation oncology groups! Kamya Sankar MD Michael D Green Garth Strohbehn @AngelQinMD

High yield #ESMO2022 data for #NSCLC.

thanks to PER for this opportunity to present MET+ NSCLC! #NSCLC #LungCancer #oncology #TargetedTherapies

Are you interested in a career in thoracic oncology? The IASLC seeks early-career physicians to participate in the 2022-23 IASLC Academy, a program shared through 4 virtual meetings & a live workshop @ #WCLC23. Applications close Oct. 3, 2022. Learn more: bit.ly/3LjT1yf

Our review on sotorasib for treatment of KRAS G12C NSCLC! @AngelQinMD Garth Strohbehn tandfonline.com/doi/full/10.10…

Real-world analysis of durvalumab in veteran population described in IASLC #ILCN piece by Dr. Kamya Sankar MD - while OS shorter in this real-world population, benefit compared to pre-durvalumab era still noted. Illustrates the gap and need for more RWE data ilcn.org/when-perfect-i…

Incredibly honored to receive the ASCO Career Development Award this year to study immunotherapy resistance in lung cancer metastatic to liver. Thankful for all my mentors along the way Michael D Green, Dr. Ramnath, Dr. K, Dr. Bhowmick, and Karen Reckamp, MD, MS. Cancer at Cedars-Sinai #conquercancer

Thank you Cedars-Sinai Academic Medicine!

Thank you Conquer Cancer, the ASCO Foundation #ASCO2023 Cancer at Cedars-Sinai Cedars-Sinai Academic Medicine

Excited to share this collaborative paper on designing pragmatic cancer clinical trials. #ProjectPragmatica FDA Oncology SWOG Cancer Research Network Karen Reckamp Roy Herbst Jhanelle Gray MD Wade Iams ascopubs.org/doi/full/10.12…

Effectiveness and safety of immune checkpoint inhibitors in Black patients versus White patients in a US national health system: a retrospective cohort study Out on Lancet Oncology This retrospective cohort study aimed to evaluate the effectiveness and safety of immune

With abundant approved ICI regimens, do we need another option for 1L metastatic NSCLC? Dr. Reckamp and I analyze HARMONi-2 in The Lancet Karen Reckamp, MD, MS Cancer at Cedars-Sinai Cedars-Sinai thelancet.com/journals/lance…

Presenting our work on immune landscape of liver mets in advanced lung cancer at #ASCO25, thanks to Conquer Cancer, the ASCO Foundation Neil Bhowmick Karen Reckamp, MD, MS Cancer at Cedars-Sinai.

Congratulations to our Cancer at Cedars-Sinai Division Director Karen Reckamp, MD, MS‼️ Kamya Sankar MD

DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] Kamya Sankar MD et al. Karen Reckamp, MD, MS Lung Cancer lungcancerjournal.info/article/S0169-… #lcsm #ImmunoOnc #PrecisionMedicine Tempus

Congratulations to our 2nd year Hematology/Oncology fellow Louisa Liu on receiving the ASCO YIA this year for her research on the effects of time restricted eating on the gut microbiome in rectal cancer! Mentored by Dr. Figueiredo and Jun Gong. Cancer at Cedars-Sinai

Congratulations to our inaugural graduating Hematology/Oncology fellows! We are excited to see where your careers will take you. Cancer at Cedars-Sinai Dr. Andrew Hendifar Akil Merchant Karen Reckamp, MD, MS